Cytyc gains FDA OK for ThinPrep vial testing:
This article was originally published in Clinica
Executive Summary
The US FDA has approved testing for Chlamydia trachomatis (CT) and Neisseria gonorrhoea (NG) directly from Cytyc's ThinPrep Pap test collection vial using Roche Diagnostics' COBAS AMPLICOR automated system. The approval allows physicians to check for chlamydia and gonorrhoea infections, plus human papilloma virus infection and cervical lesions using a single ThinPrep Pap test specimen, says Boxborough, Massachusetts-based Cytyc. Chlamydia is the most common bacterial sexually transmitted disease in the US and is asymptomatic in around 75% of cases.